Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs ...

Vilastobart in combination with atezolizumab continued to demonstrate a differentiated and generally well-tolerated safety profile. Treatment-related adverse events (AEs) were primarily Grade 1 or 2, ...

Ended the third quarter with $380.5 million in cash, cash equivalents and short-term marketable debt securities which, together with funds from a ...

As Tubulis prepares to unveil the first in-human data on its next-generation antibody drug conjugate (ADC) later this month, the German biotech has secured a massive new financing round to kick its ...

Jay will begin with a review of recent corporate updates and discuss our clinical programs for DuraVu in wet AMD and DME.

Renton, Wash.-based Providence and Humana are collaborating on a new data exchange model to boost value-based care. The 51-hospital system and payer giant say they plan to go live in October with ...

UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting new data highlighting insights on patient outcomes with rozanolixizumab and zilucoplan for ...

WASHINGTON (Reuters) -The White House said on Friday there likely will not be a release of inflation data next month due to the U.S. government shutdown. Because of Congress' failure to pass a stopgap ...

Regeneron has posted updated clinical data on DB-OTO, providing more evidence of the gene therapy’s potential to treat a rare genetic form of deafness as it plans for a potential FDA filing later this ...

Axuall, the industry leader in clinical workforce intelligence, and the world-renowned Cleveland Clinic today announced a ...

ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing ...